Drug intelligence / Profile preview

1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea

Development stage
Unknown
Modality
Small Molecules
01

Overview

This compound is an experimental small molecule belonging to the class of aminopyrimidines and derivatives. It is identified by its IUPAC name and has a molecular formula of C18H17F3N10O2S with a molecular weight of approximately 494.45 Da[1][5]. The compound acts as an inhibitor of serine/threonine-protein kinase PLK1 (Polo-like kinase 1), with an IC50 value of approximately 720 nM[1]. PLK1 is involved in cell cycle regulation and mitosis; inhibition can lead to disruption of cell division and may have antitumor effects. There are no approved indications or marketed products for this molecule; it remains at the experimental stage.

Other names
1-[5-Methyl-2-(trifluoromethyl)-3-furyl]-3-[5-(2-{[6-(1H-1,2,4-triazol-3/5/7/9/11/13/15-yloxy)pyrimidinyl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]ureaN-[5-methyl-2-(trifluoromethyl)-3-furanyl]-N′-[5-[2-[[6-(1H‑1,2,4‑triazol‑5‑ylamino)‑4-pyrimidinyl]amino]ethyl]-thiazolyl]-Urea
02

Targets

PLK1 (Polo like kinase 1)

Beyond the preview

Go deeper on 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call